Opening the door to personalized medicine
Lausanne/Neuchâtel, 10 December 2018—SUN bioscience launches its Gri3D™ platform. Industrialized with CSEM technological support, Gri3D™ enables the large-scale, standardized, rapid, and reliable production of 3-D in vitro organoid cultures from patient stem cells. This groundbreaking, large scale standardizing of organoids represents a key advancement toward truly personalizing medicine.
Related Press
22 February 2024
CSEM and ClexBio create a bioreactor for tissue-engineered cardiovascular implants
The teams at CSEM and at ClexBio have developed a process for engineering vein grafts comprised of human tissue material that integrates into the patient’s body and can turn into real, living tissue....
25 July 2024
CSEM develops a pioneering implant to support reproductive medicine
Swiss-based start-ups Impli and Yalosys, and the technology innovation center CSEM present an implantable biosensor for real-time fertility hormone monitoring....
24 June 2021
CUTISS
CUTISS AG, a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering, has unveiled the world’s first automated machine to produce customized skin tissue...